Cowen and Company’s Ionis Pharmaceuticals IONS Stock Holding History

Cowen and Company’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-51,415	Closed	-$2.6M	–	696
2023 Q4	$2.6M	Buy	+51,415	New	+$2.46M	0.17%	94
2022 Q2	–	Sell	-13,257	Closed	-$491K	–	703
2022 Q1	$491K	Buy	13,257 +5,527	+72%	+$181K	0.05%	161
2021 Q4	$235K	Sell	7,730 -5,113	-40%	-$161K	0.02%	285
2021 Q3	$431K	Sell	12,843 -14,865	-54%	-$560K	0.02%	204
2021 Q2	$1.1M	Buy	27,708 +20,627	+291%	+$808K	0.06%	118
2021 Q1	$318K	Buy	+7,081	New	+$395K	0.02%	228
2020 Q4	–	Sell	-8,061	Closed	-$382K	–	466
2020 Q3	$382K	Sell	8,061 -13,733	-63%	-$763K	0.06%	160
2020 Q2	$1.28M	Buy	21,794 +997	+5%	+$55.5K	0.21%	81
2020 Q1	$983K	Buy	+20,797	New	+$1.16M	0.23%	89

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cowen and Company's IONS Position: Q1 2024 in Review

Cowen and Company sold out of Ionis Pharmaceuticals (IONS) in Q1 2024, closing a stake of 51,415 shares — an estimated $2.6M sold.

Cowen and Company first reported a position in IONS in Q1 2020 and held it in 9 quarters. The position peaked at $2.6M in Q4 2023. 361 funds tracked by Wall St. Rank hold IONS as of Q1 2024.

Cowen and Company reported no remaining Ionis Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Cowen and Company sold 51,415 Ionis Pharmaceuticals shares in Q1 2024, an estimated $2.6M.
Cowen and Company first reported a position in Ionis Pharmaceuticals in Q1 2020 and held it in 9 quarters.
Cowen and Company's Ionis Pharmaceuticals position peaked at $2.6M in Q4 2023.
361 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.